Water retention in the acute phase of Kawasaki disease: relationship between oedema and the development of coronary arterial lesions.
Despite intravenous immunoglobulin therapy, a certain percentage of patients with Kawasaki disease (KD) still develop coronary arterial lesions (CAL). In an effort to find new combined therapies to reduce the incidence of CAL, we focused on the oedema which can be an important sign of the increased vascular permeability in KD. A total of 127 patients with KD were included in the retrospective study. Serial weekly changes in serum sodium and albumin levels from the 1st to the 4th week of illness were examined. In addition, the maximum rate of increase in body weight from admission to the 14th day of illness was evaluated. Serum sodium levels (mEq/l) in only the 2nd week of illness were significantly lower in patients with CAL than in those without CAL (mean +/- SD, 135.5+/-4.5 versus 138.0+/-2.4, P<0.05). Serum albumin levels in all 4 weeks were significantly lower in patients with CAL than in those without CAL ( P<0.001). The maximum rate (%) of increase in body weight from admission to the 14th day of illness was significantly higher in patients with CAL than in those without CAL (ranges and median values, 0-12.3 (7.0) versus 0-10.3 (3.2), P<0.001).


CONCLUSIONS
these results suggest that water retention in the acute phase of Kawasaki disease may be a risk factor for CAL, and water intake of both infusion and oral intake should be kept to a minimum in order to avoid progressive oedema.
Suzuki
Hiroyuki
H
Department of Paediatrics, Wakayama Medical University, 811-1 Kimiidera, 641-0012, Wakayama, Japan. hsuzuki@wakayama-med.ac.jp
Takeuchi
Takashi
T
Minami
Takaomi
T
Shibuta
Shoichi
S
Uemura
Shigeru
S
Yoshikawa
Norishige
N
D000208:Acute Disease; D002648:Child; D002675:Child, Preschool; D003327:Coronary Disease / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D004487:Edema / Q000097:blood / Q000150:complications* / Q000517:prevention & control; D005260:Female; D005440:Fluid Therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D007564:Japan / Q000453:epidemiology; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications* / Q000628:therapy; D012189:Retrospective Studies; D012307:Risk Factors; D018709:Statistics, Nonparametric
D016756:Immunoglobulins, Intravenous